<DOC>
	<DOCNO>NCT00296010</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , methotrexate , cyclophosphamide , liposomal doxorubicin , work different way stop growth tumor cell , either kill cell stop divide . Giving chemotherapy surgery may kill tumor cell remain surgery . It yet know whether give liposomal doxorubicin surgery effective observation cyclophosphamide methotrexate treat breast cancer . PURPOSE : This randomized phase III trial study liposomal doxorubicin see well work compare observation cyclophosphamide methotrexate treat old woman undergo surgery breast cancer .</brief_summary>
	<brief_title>Liposomal Doxorubicin Compared With Observation Cyclophosphamide Methotrexate Treating Older Women Who Have Undergone Surgery Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare breast cancer-free interval elderly woman resectable , hormone receptor-negative breast cancer treat pegylated doxorubicin hydrochloride liposome ( PDL ) v observation PDL v cyclophosphamide methotrexate . Secondary - Compare tolerability regimens patient . - Compare safety toxic effect regimens patient . - Compare overall progression-free survival patient treat regimen . - Compare quality life patient treat regimen . - Compare sit failure patient treat regimen . - Compare compete cause death patient treat regimen . - Compare rate second non-breast malignancy patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center . Patients assign , base patient preference , 1 2 treatment group . - Group 1 : Patients randomize 1 2 arm ( arm I II ) . - Arm I : Patients receive pegylated doxorubicin hydrochloride liposome ( PDL ) IV 1 hour day 1 . Treatment repeat every 2 week 8 course absence disease progression unacceptable toxicity . - Arm II : Patients undergo observation . - Group 2 : Patients randomize 1 2 treatment arm ( arm III IV ) . - Arm III : Patients receive PDL arm I . - Arm IV : Patients receive oral cyclophosphamide daily day 1-7 oral methotrexate twice daily day 1 4 . Treatment repeat every week 16 course absence disease progression unacceptable toxicity . All patient may undergo radiotherapy accord institutional standard either surgery completion chemotherapy . Quality life assess baseline 3 , 6 , 12 month . After completion study treatment , patient follow periodically 1 year . PROJECTED ACCRUAL : A total 1,296 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Disease must confine breast axillary node without detected mass elsewhere No history prior ipsilateral contralateral invasive breast cancer Resected disease No 16 week since last surgery remove tumor No known clinical residual locoregional disease Margins must negative invasive breast cancer ductal carcinoma situ No locally advance , inoperable breast cancer include follow : Inflammatory breast cancer Supraclavicular node involvement Enlarged internal mammary node unless pathologically negative Synchronous bilateral invasive breast cancer ( diagnose past 2 month ) allow tumor hormone receptornegative Must candidate endocrine therapy standard chemotherapy Hormone receptornegative disease PATIENT CHARACTERISTICS : Female Menopausal status : postmenopausal ECOG performance status 02 Platelet count ≥ 100,000/mm^3 Granulocyte count ≥ 1,500/mm^3 WBC ≥ 3,000/mm^3 AST ALT ≤ 1.5 time upper limit normal ( ULN ) Bilirubin normal Creatinine clearance ≥ 50 mL/min Creatinine &lt; 1.35 mg/dL No significant malabsorption syndrome disease affect gastrointestinal tract function No myocardial infarction within past 6 month No pulmonary embolism within past 6 month No deep vein thrombosis within past 6 month No New York Heart Association class III IV heart disease LVEF ≥ 50 % echocardiography , radionucleotide ventriculography , MUGA No evidence acute ischemia ECG No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix bladder , ipsilateral contralateral breast carcinoma situ No active , uncontrolled infection No active hepatitis B C virus infection No chronic infection Patients must follow `` geriatric syndrome '' : Dementia Delirium Major depression ( diagnosed psychiatrist ) Recent fall Spontaneous bone fracture Neglect Abuse No evidence medically relevant conduction system abnormality would preclude study entry No nonmalignant , uncontrolled systemic disease , psychiatric illness , addictive cognitive disorder would preclude study participation compliance PRIOR CONCURRENT THERAPY : At least 4 week since prior raloxifene , tamoxifen citrate , selective estrogen receptor modulators ( SERMs ) No concurrent recombinant human epoetin alfa pegfilgrastim No prior neoadjuvant adjuvant therapy breast cancer except radiotherapy Concurrent trastuzumab ( Herceptin® ) allow No concurrent hormonal replacement therapy No concurrent hormonal therapy ( include estrogen , progesterone , androgen , tamoxifen citrate , SERMs , aromatase inhibitor ) except follow : Steroids adrenal failure Hormones nondiseaserelated condition ( e.g. , insulin diabetes ) Intermittent dexamethasone antiemetic No concurrent investigational agent No concurrent bisphosphonates , except treatment osteoporosis For patient receive prior anthracyclines , follow criterion must meet : Cumulative dose ≤ 240 mg/m² conventional doxorubicin ≤ 140 mg/m² case prior doxorubicin leave chest radiotherapy ( LCRT ) Cumulative dose ≤ 400 mg/m² epirubicin ≤ 230 mg/m² case prior epirubicin LCRT</criteria>
	<gender>Female</gender>
	<minimum_age>66 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>